Eli Lilly's Zepbound Outperforms Novo Nordisk's Wegovy in Obesity Drug Trial Amidst Market Competition

Eli Lilly's Zepbound has emerged as a potent contender against Novo Nordisk's Wegovy in the competitive obesity drug market. The recent SURMOUNT-5 trial results revealed that Zepbound induced a 20.2% average weight loss over 18 months, compared to Wegovy's 13.7%, translating to an average weight loss of 50 pounds with Zepbound versus 33 pounds with Wegovy[1][2]. This head-to-head study conducted with 751 participants, who were overweight or obese without diabetes, showcased that Zepbound's dual-action mechanism targeting two gut hormones offers a significant advantage over Wegovy's single-hormone approach[2]. These findings position Zepbound as a formidable option in the weight loss industry, which is poised to surpass $100 billion in annual sales[1].